Premium
P1‐150: The Italian Alzheimer's Disease Neuroimaging Initiative (IADNI)
Author(s) -
Cavedo Enrica,
Babiloni Claudio,
Redolfi Alberto,
Lizio Roberta,
Chiapparini Luisa,
Sabatini Umberto,
Soricelli Andrea,
Vernieri Fabrizio,
Sinforiani Elena,
Tedeschi Gioacchino,
Marino Silvia,
Bruzzone Maria Grazia,
Acquino Domenico,
Alesiani Marcella,
Cherubini Andrea,
Salvatore Elena,
Angeloni Francesco,
Scrascia Federica,
Chiarati Patrizia,
Vitali Paolo,
Montella Patrizia,
Corbo Daniele,
Baglieri Annalisa,
Bramanti Placido,
Carducci Filippo,
Quattrocchi Carlo,
Frisoni Giovanni
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.427
Subject(s) - neuroimaging , alzheimer's disease neuroimaging initiative , dementia , memory clinic , medicine , neuropsychological assessment , magnetic resonance imaging , neuropsychology , psychology , disease , cognition , psychiatry , radiology
Background: It has been proposed that different biomarkers could help in the diagnosis of mild cognitive impairment (MCI) and dementia due to Alzheimer’s disease (AD). We capitalized on data from two different clinical series to characterize and compare the sensitivity and specificity of different AD biomarkers to predict progression fromMCI to AD dementia over a 2636 months period. Methods: Magnetic resonance imaging (MRI) hippocampal volumes, flourodeoxyglucose positron emission tomography (PET) hypometabolic indices, and cerebrospinal fluid (CSF) Abeta42 and total tau levels were compared in 18 MCI patients from the Translational Outpatient Memory Clinic (TOMC) in Brescia, Italy, who progressed to probable AD dementia and in 18 MCI patients who remained stable during the same follow-up period. These measurements were also compared in 24 MCI patients from the ADNeuroImaging Initiative (ADNI) who progressed to probable AD dementia and 33 MCI patients who remained stable during the same follow-up period. An AD-related pattern of cerebral hypometabolism was measured in different ways (PALZ score, MetaROI, and the hypometabolic convergence index HCI), medial temporal atrophy was measured by manual and automatic hippocampal volumetry, and CSF markers were Abeta42 and total tau assays. Biomarker abnormalities were categorized using previously published or independently computed cutoffs. Sensitivity for pAD and AD dementia, specificity for sMCI and healthy elderly, and classification accuracy of each biomarker were computed. Results: Sensitivity to predict conversion fromMCI to probable AD during the 26-36 months follow-up period in the respective ADNI and TOMC cohorts was 79% and 94% using low Abeta42, 46% and 28% using smaller hippocampal volumes, 33-66% and 56-78% using the different hypometabolic indices, and 46% and 61% using total tau levels. Specificity to exclude sMCI during the same follow-up period was 27% and 50% using low Abeta42, 76% and 94% using smaller hippocampal volumes, 58-67% and 55-83% using the different hypometabolic indices, and 61% and 83% using total tau levels. Conclusions: Preliminary findings from the two study cohorts suggest the Abeta42 and hippocampal measurements may be used in combination to which MCI patients do or do not progress to AD over 26-36 months with the greatest accuracy.